Over the last 15 years, the field of mechanical circulatory support (MCS) has enjoyed a rapid
technological evolution, leading to marked gains in patient survival. In 2010, average 1-year …

The twelfth annual report from The Society of Thoracic Surgeons (STS) Interagency Registry
for Mechanically Assisted Circulatory Support (Intermacs) highlights outcomes for 26 688 …

ACCORDING TO THE American Heart Association 2010 update, more than 5.7 million
people in the United States suffer from heart failure. 1-3 The prevalence of heart failure in …

Background The literature examining clinical outcomes and readmissions during extended
(> 1 yr) left ventricular assist device (LVAD) support is scarce, particularly in the era of …

This study aims to identify the major components of left ventricular assist device (LVAD)-
related costs in a population on long-term mechanical circulatory support to gain insight into …

In the current era, continuous-flow left ventricular assist devices (LVADs)—mainly the
HeartWare HVAD (HW) and HeartMate 3 (HM3)—are the preferred mechanical circulatory …

Background Left ventricular assist devices (LVADs) have shown survival benefit in end-
stage heart failure patients. LVAD technology has evolved considerably with the …

Patients with end-stage heart failure have grim survival and quality of life. Average health
status measures are worse than for advanced cancer. 1 Within this context, it is not …

Feature Editor's Note—The burdening costs of heart failure care continue to rapidly escalate
as the prevalence of heart failure increases with the aging of the US population. Durable left …

Left ventricular assist devices (LVADs) improve survival and quality of life (QOL) for most, but
not all, patients with advanced heart failure. We described a broader definition of poor …